Patents by Inventor Aleksander Hinek
Aleksander Hinek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240374618Abstract: Compositions, kits, and methods that can be used to improve elastin concentration are described herein. For example, pharmaceutical compositions described herein comprise a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is tannic acid, ellagic acid, or combinations thereof, and the second agent is vitamin D, hyaluronic acid, ferulic acid, or combinations thereof.Type: ApplicationFiled: November 15, 2023Publication date: November 14, 2024Inventors: Aleksander HINEK, Thomas F. MITTS
-
Publication number: 20230073764Abstract: Compositions, kits, and methods that can be used to improve elastin concentration are described herein. For example, pharmaceutical compositions described herein comprise a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is tannic acid, ellagic acid, or combinations thereof, and the second agent is vitamin D, hyaluronic acid, ferulic acid, or combinations thereof.Type: ApplicationFiled: May 17, 2022Publication date: March 9, 2023Inventors: Aleksander HINEK, Thomas F. MITTS
-
Publication number: 20210277072Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.Type: ApplicationFiled: October 15, 2020Publication date: September 9, 2021Applicants: ELASTOGENESIS, LLC, THE HOSPITAL FOR SICK CHILDRENInventors: Felipe JIMENEZ, Thomas MITTS, Aleksander HINEK
-
Patent number: 10844101Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.Type: GrantFiled: November 27, 2018Date of Patent: November 24, 2020Assignees: Elastogenesis, LLC, The Hospital for Sick ChildrenInventors: Felipe Jimenez, Thomas Mitts, Aleksander Hinek
-
Publication number: 20190153045Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.Type: ApplicationFiled: November 27, 2018Publication date: May 23, 2019Applicants: HUMAN MATRIX SCIENCES, LLC, THE HOSPITAL FOR SICK CHILDRENInventors: Felipe Jimenez, Thomas Mitts, Aleksander Hinek
-
Patent number: 10167325Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.Type: GrantFiled: June 20, 2016Date of Patent: January 1, 2019Assignees: Human Matrix Sciences, LLC, The Hospital for Sick ChildrenInventors: Felipe Jimenez, Thomas Mitts, Aleksander Hinek
-
Patent number: 10004779Abstract: Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra-tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin and prevention and treatment of degradation of dermal elastic fibers.Type: GrantFiled: December 8, 2015Date of Patent: June 26, 2018Assignees: Human Matrix Services, LLC, The Hospital for Sick ChildrenInventors: Thomas Mitts, Felipe Jimenez, Aleksander Hinek
-
Patent number: 9867804Abstract: Embodiments provide methods for using ascorbate for the stimulation of production of elastic fibers by cells.Type: GrantFiled: June 28, 2016Date of Patent: January 16, 2018Assignees: Human Matrix Sciences, LLC, The Hospital for Sick ChildrenInventors: Thomas F. Mitts, Aleksander Hinek, Hyunjun Jonathan Kim
-
Publication number: 20170002047Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.Type: ApplicationFiled: June 20, 2016Publication date: January 5, 2017Applicants: HUMAN MATRIX SCIENCES, LLC, THE HOSPITAL FOR SICK CHILDRENInventors: Felipe JIMENEZ, Thomas MITTS, Aleksander HINEK
-
Patent number: 9492462Abstract: Compositions and methods for inducing the deposition of elastin in skin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.Type: GrantFiled: June 21, 2013Date of Patent: November 15, 2016Assignees: Human Matrix Sciences, LLC, The Hospital for Sick ChildrenInventors: Aleksander Hinek, Thomas Mitts
-
Publication number: 20160303071Abstract: Embodiments provide methods for using ascorbate for the stimulation of production of elastic fibers by cells.Type: ApplicationFiled: June 28, 2016Publication date: October 20, 2016Applicants: HUMAN MATRIX SCIENCES, LLC, THE HOSPITAL FOR SICK CHILDRENInventors: Thomas F. MITTS, Aleksander HINEK, Hyunjun Jonathan KIM
-
Patent number: 9422334Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.Type: GrantFiled: August 26, 2013Date of Patent: August 23, 2016Assignees: The Hospital For Sick Children, Human Matrix Sciences, LLCInventors: Felipe Jimenez, Thomas Mitts, Aleksander Hinek
-
Patent number: 9387194Abstract: Embodiments provide methods for using ascorbate for the stimulation of production of elastic fibers by cells.Type: GrantFiled: January 18, 2013Date of Patent: July 12, 2016Assignees: Human Matrix Sciences, LLC, The Hospital For Sick ChildrenInventors: Thomas F. Mitts, Aleksander Hinek, Hyunjun Jonathan Kim
-
Publication number: 20160089415Abstract: Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra- tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin and prevention and treatment of degradation of dermal elastic fibers.Type: ApplicationFiled: December 8, 2015Publication date: March 31, 2016Inventors: Thomas MITTS, Felipe JIMENEZ, Aleksander HINEK
-
Patent number: 9283236Abstract: Compositions and methods for inducing the deposition of elastin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.Type: GrantFiled: October 18, 2013Date of Patent: March 15, 2016Assignees: The Hospital for Sick Children, Human Matrix Sciences, LLCInventors: Aleksander Hinek, Thomas F. Mitts
-
Patent number: 9254300Abstract: Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra-tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin and prevention and treatment of degradation of dermal elastic fibers.Type: GrantFiled: January 8, 2014Date of Patent: February 9, 2016Assignees: Human Matrix Sciences, LLC, The Hospital for Sick ChildrenInventors: Thomas Mitts, Felipe Jimenez, Aleksander Hinek
-
Publication number: 20150359854Abstract: Compositions and methods for modulating the deposition of elastin by administering compositions including insulin receptor agonists are described herein.Type: ApplicationFiled: June 8, 2015Publication date: December 17, 2015Applicants: THE HOSPITAL FOR SICK CHILDREN, HUMAN MATRIX SCIENCES, LLCInventors: Thomas F. MITTS, Aleksander HINEK
-
Publication number: 20150110755Abstract: The present invention describes therapeutic compositions comprising fibroblasts that have been stimulated to increase expression of extracellular matrix components or elastin, or to produce enhanced elastogenesis or the appearance thereof at a site of administration. The therapeutic fibroblast formulations can be prepared using a variety of elastogenic agents, including digests of mammalian elastin, chemically digested plant extracts comprising elastin-like peptides, and synthetic elastogenic peptides. The invention further comprises cosmetic and pharmaceutical treatment methods using the therapeutic fibroblast compositions of the invention.Type: ApplicationFiled: October 25, 2014Publication date: April 23, 2015Inventors: Felipe JIMENEZ, Thomas MITTS, Aleksander HINEK
-
Patent number: 9006170Abstract: The present invention describes therapeutic compositions comprising one or more minerals, including trivalent iron, divalent manganese and salts thereof, suitable in facilitating synthesis and deposition of connective tissue matrix, particularly rich of elastin and collagen, and mitogenic potential in human dermal fibroblasts. It also describes the phenomenon in which stimulation of elastogenesis by arterial SMC associates with a net decrease in proliferation of these cell types. The present invention also describes methods of treatment of human skin fibroblasts and arterial smooth muscle cells. The therapeutic compositions of the present invention comprise one or more of trivalent iron or divalent manganese or salts thereof and may be combined with an elastic tissue digest.Type: GrantFiled: January 12, 2010Date of Patent: April 14, 2015Assignees: Human Matrix Sciences, LLC, The Hospital for Sick ChildrenInventors: Thomas Mitts, Felipe Jimenez, Aleksander Hinek, Severa Bunda
-
Patent number: 8871707Abstract: The present invention describes therapeutic compositions comprising fibroblasts that have been stimulated to increase expression of extracellular matrix components or elastin, or to produce enhanced elastogenesis or the appearance thereof at a site of administration. The therapeutic fibroblast formulations can be prepared using a variety of elastogenic agents, including digests of mammalian elastin, chemically digested plant extracts comprising elastin-like peptides, and synthetic elastogenic peptides. The invention further comprises cosmetic and pharmaceutical treatment methods using the therapeutic fibroblast compositions of the invention.Type: GrantFiled: September 16, 2010Date of Patent: October 28, 2014Assignees: Human Matrix Sciences, LLC, The Hospital for Sick ChildrenInventors: Felipe Jimenez, Thomas F. Mitts, Aleksander Hinek